Cargando…
Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660403/ https://www.ncbi.nlm.nih.gov/pubmed/38020728 http://dx.doi.org/10.1002/cti2.1474 |
_version_ | 1785148402415173632 |
---|---|
author | Haycroft, Ebene R Damelang, Timon Lopez, Ester Rodgers, Mark A Wines, Bruce D Hogarth, Mark Ameel, Cassaundra L Kent, Stephen J Scanga, Charles A O'Connor, Shelby L Chung, Amy W |
author_facet | Haycroft, Ebene R Damelang, Timon Lopez, Ester Rodgers, Mark A Wines, Bruce D Hogarth, Mark Ameel, Cassaundra L Kent, Stephen J Scanga, Charles A O'Connor, Shelby L Chung, Amy W |
author_sort | Haycroft, Ebene R |
collection | PubMed |
description | OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS: Here, we used a simian immunodeficiency virus (SIV)/TB‐coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV‐negative (n = 8) and SIV‐positive (n = 7) MCM 8‐week postinfection with Mycobacterium tuberculosis (Mtb). RESULTS: Antibody responses to Mtb were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8‐week post‐Mtb infection, including increased agalactosylation (G0) and reduced di‐galactosylation (G2), which correlated with endpoint Mtb bacterial burden and gross pathology scores, as well as the time‐to‐necropsy. CONCLUSION: These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression. |
format | Online Article Text |
id | pubmed-10660403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106604032023-11-20 Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques Haycroft, Ebene R Damelang, Timon Lopez, Ester Rodgers, Mark A Wines, Bruce D Hogarth, Mark Ameel, Cassaundra L Kent, Stephen J Scanga, Charles A O'Connor, Shelby L Chung, Amy W Clin Transl Immunology Short Communication OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS: Here, we used a simian immunodeficiency virus (SIV)/TB‐coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV‐negative (n = 8) and SIV‐positive (n = 7) MCM 8‐week postinfection with Mycobacterium tuberculosis (Mtb). RESULTS: Antibody responses to Mtb were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8‐week post‐Mtb infection, including increased agalactosylation (G0) and reduced di‐galactosylation (G2), which correlated with endpoint Mtb bacterial burden and gross pathology scores, as well as the time‐to‐necropsy. CONCLUSION: These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression. John Wiley and Sons Inc. 2023-11-20 /pmc/articles/PMC10660403/ /pubmed/38020728 http://dx.doi.org/10.1002/cti2.1474 Text en © 2023 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Haycroft, Ebene R Damelang, Timon Lopez, Ester Rodgers, Mark A Wines, Bruce D Hogarth, Mark Ameel, Cassaundra L Kent, Stephen J Scanga, Charles A O'Connor, Shelby L Chung, Amy W Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques |
title | Antibody glycosylation correlates with disease progression in SIV‐
Mycobacterium tuberculosis coinfected cynomolgus macaques |
title_full | Antibody glycosylation correlates with disease progression in SIV‐
Mycobacterium tuberculosis coinfected cynomolgus macaques |
title_fullStr | Antibody glycosylation correlates with disease progression in SIV‐
Mycobacterium tuberculosis coinfected cynomolgus macaques |
title_full_unstemmed | Antibody glycosylation correlates with disease progression in SIV‐
Mycobacterium tuberculosis coinfected cynomolgus macaques |
title_short | Antibody glycosylation correlates with disease progression in SIV‐
Mycobacterium tuberculosis coinfected cynomolgus macaques |
title_sort | antibody glycosylation correlates with disease progression in siv‐
mycobacterium tuberculosis coinfected cynomolgus macaques |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660403/ https://www.ncbi.nlm.nih.gov/pubmed/38020728 http://dx.doi.org/10.1002/cti2.1474 |
work_keys_str_mv | AT haycroftebener antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT damelangtimon antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT lopezester antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT rodgersmarka antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT winesbruced antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT hogarthmark antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT ameelcassaundral antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT kentstephenj antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT scangacharlesa antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT oconnorshelbyl antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques AT chungamyw antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques |